Chinese biotechnology company selling in-vitro diagnostic reagents; exact test-menu scope not fully confirmed.
Chinese biotechnology company selling in-vitro diagnostic reagents; exact test-menu scope not fully confirmed.
Moat: none
Headquarters: Beijing, China · Employees: 998
Size Beijing Strong Biotechnologies (300406.SZ) is a China Health Care company (Medical Specialties) with a market value of $1.13B, the 1927th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.60 on 18 Nov 2026.
Performance Over six months the shares fell 3.5%, against -9.9% for the median peer and -20.0% for the China market (cap-weighted) — 8th highest of 20 in its peer set.
Growth Revenue fell 4.1% over the last twelve months (peer median +10.4%); the operating margin is 35.9% (peer median 8.0%).
Valuation It trades at 18.2× forward earnings against a peer median of 23.9× (5th cheapest of 12).
Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -8 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.7 points above its cost of capital (6.3% WACC).
Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.37B | CN¥1.34B | CN¥1.65B | CN¥1.73B | CN¥1.50B |
| Revenue growth | — | -19% | -5% | +15% | — |
| Gross profit | CN¥1.12B | CN¥1.01B | CN¥1.23B | CN¥1.24B | CN¥1.07B |
| EBITDA | n/a | CN¥479M | CN¥705M | CN¥674M | CN¥555M |
| Net income | CN¥251M | CN¥190M | CN¥538M | CN¥524M | CN¥389M |
| Free cash flow | CN¥559M | CN¥526M | CN¥568M | CN¥442M | CN¥310M |
| Capital expenditure | CN¥21.5M | CN¥39.2M | CN¥67.6M | CN¥148M | CN¥96.5M |
| Total debt | CN¥1.10B | CN¥1.07B | CN¥1.18B | CN¥1.19B | CN¥1.12B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300406.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.4% | -6.0% | 4th highest of 21 |
| 6-month return | -3.5% | -9.9% | 8th highest of 20 |
| Distance from 52-week high | -21.5% | -37.5% | 3rd highest of 21 |
| Revenue growth (TTM) | -4.1% | +10.4% | 4th lowest of 19 |
| Operating margin | 35.9% | 8.0% | 3rd highest of 20 |
| Forward P/E | 18.2× | 23.9× | 5th cheapest of 12 |
| Growth the price implies (Req g, 7 yrs) | 1.7% | 9.6% | 3rd least demanding of 11 |
| Growth delivered (Del g) | +9.9% | +10.4% | 6th highest of 11 |
| Hurdle (Req g minus delivered) | -8.2 pp | -1.5 pp | 3rd least demanding of 11 |
| ROIC minus cost of capital | +3.7 pp | -2.5 pp | 6th highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | -4% | -4% | 36% | 18.2× | 1.7% | +9.9% |
| Shandong Weigao Orthopaedic Device 688161.SS | China | $1.14B | -29% | -6% | 18% | 24.9× | 11.3% | -3.5% |
| Alpha Tau Medical DRTS | United States | $1.11B | +7% | n/a | n/a | n/a | n/a | n/a |
| Alphatec ATEC | United States | $1.10B | -14% | +15% | -3% | 15.1× | n/a | n/a |
| Freenome FRNM | United States | $1.08B | n/a | n/a | 36% | n/a | n/a | n/a |
| CLASSYS 214150.KS | South Korea | $1.08B | -60% | +16% | 43% | 13.7× | -9.2% | +34.5% |
| Integra LifeSciences IART | United States | $1.08B | -10% | +1% | 12% | 6.0× | 5.9% | +3.6% |
| Tandem Diabetes Care TNDM | United States | $1.19B | +13% | +7% | -2% | n/a | n/a | n/a |
| Mingyue Optical Lens 301101.SZ | China | $1.07B | -4% | +14% | 25% | 31.6× | 8.8% | +8.8% |
| Guangzhou Hexin Instrument 688622.SS | China | $1.06B | +21% | -29% | -74% | n/a | n/a | n/a |
| SI-BONE SIBN | United States | $1.06B | +59% | +14% | -8% | n/a | n/a | n/a |
| Shenzhen Edge Medical 2675.HK | Hong Kong | $1.21B | -51% | +132% | 2% | 120.2× | n/a | n/a |
| IRadimed IRMD | United States | $1.05B | -9% | +11% | 32% | 34.3× | 18.5% | +21.5% |
| Eyebright Medical Technology (Beijing) 688050.SS | China | $1.21B | -16% | +21% | 16% | 23.9× | 10.3% | +40.3% |
| Castle Biosciences CSTL | United States | $1.03B | +67% | +10% | -7% | n/a | 57.7% | +40.6% |
| Eckert & Ziegler EUZ.DE | Germany | $1.03B | -2% | +4% | 26% | 18.5× | 7.7% | +12.1% |
| Sansure Biotech 688289.SS | China | $1.24B | -17% | -1% | 1% | 35.6× | n/a | n/a |
| Beijing Wandong Medical Technology 600055.SS | China | $1.03B | -26% | -11% | -33% | n/a | n/a | n/a |
| Inno Laser Technology 301021.SZ | China | $1.03B | -33% | +17% | 9% | n/a | 50.8% | +8.6% |
| PHC 6523.T | Japan | $1.02B | +34% | +3% | 8% | 7.5× | -4.0% | +3.5% |
| NovoCure NVCR | United States | $1.25B | -40% | +13% | -17% | n/a | n/a | n/a |